Loading
Loading
Research Overview
Master intracellular antioxidant tripeptide (Glu-Cys-Gly); directly neutralises reactive oxygen species, regenerates vitamins C and E, supports phase II hepatic detoxification, and is essential for T-lymphocyte proliferation and NK cell activity.
Glutathione is a tripeptide (Glu-Cys-Gly) synthesised intracellularly through a two-step enzymatic process and maintained at millimolar concentrations in most cell types. It functions as the primary cellular antioxidant by donating electrons to neutralise reactive oxygen species, being oxidised in the process to glutathione disulphide (GSSG), which is reduced back to GSH by glutathione reductase using NADPH. Preclinical research has used cell culture and animal models to study glutathione's roles in protecting cellular components from oxidative damage, detoxifying reactive electrophiles through glutathione-S-transferase reactions, and regulating immune cell function.
In preclinical liver research, glutathione has been extensively studied as a central determinant of hepatocellular resistance to oxidative and xenobiotic injury. Liver cells contain particularly high glutathione concentrations, and preclinical hepatotoxicity models have used glutathione depletion and supplementation approaches to characterise the protective roles of GSH in hepatocyte survival under toxic challenge conditions.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, glutathione (gsh) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Glutathione (GSH) research is most relevant to protocols examining:
Oxidative stress and antioxidant defence research
Hepatoprotection and phase II detoxification studies
Immune function and NK cell activity investigations
Researchers studying skin health and pigmentation (IV glutathione)
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Primary outcomes are typically strongest in this window. Human trial literature provides benchmarks for comparison.
Washout & review
Allow full washout (~5× half-life: ~Hours). Review data, confirm baseline recovery before any repeat protocol.
Master intracellular antioxidant tripeptide (Glu-Cys-Gly); directly neutralises reactive oxygen species, regenerates vitamins C and E, supports phase II hepatic detoxification, and is essential for T-lymphocyte proliferation and NK cell activity.
| Parameter | Value |
|---|---|
| Dose range | 600–1500 mg/day (IV or sub-q) |
| Schedule | Daily or multiple times weekly |
| Route | Subcutaneous, Intravenous, Oral (limited bioavailability) |
| Half-life | ~Hours |
limited bioavailability)
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.